Accessibility Menu
Lakewood-Amedex Biotherapeutics logo

Lakewood-Amedex Biotherapeutics(NASDAQ) LABT

Market Cap$5.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-97%
5 YearN/A
1 YearN/A
1 Month+24%
$2.50
+8.70%
+0.20Today
After hours$3.12+$0.62 (+24.80%)
Lakewood-Amedex Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.502026-08-31
Lakewood-Amedex Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+17.37%USD 2.132026-08-24
1 month+23.76%USD 2.022026-07-31
3 month-59.68%USD 6.202026-06-02
Since inception-97.11%USD 86.502026-04-23

Lakewood-Amedex Biotherapeutics Financials at a Glance

Market Cap

$5.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.35M

EPS (TTM)

-$10.34

P/E Ratio

-0.24

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$2.50

Volume

502,835

Open

$2.23

Previous Close

$2.50

Daily Range

$2.22 - $2.58

52-Week Range

$1.66 - $98.20

Estimated Earnings Date

Aug 28, 2026

LABT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics Inc. is a biopharmaceutical company focused on developing innovative antimicrobial therapies. The company specializes in anti-infective products targeting specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C.

Products and Services
  • Innovative antimicrobial therapies for viral infections
  • Research and development of anti-infective products
  • Focus on addressing unmet medical needs in infectious diseases
Growth Outlook
  • Strong pipeline of antimicrobial therapies in development
  • Increasing global demand for effective antiviral treatments
  • Potential partnerships to enhance research capabilities and market reach
Financial Highlights
  • Recent quarterly net income of -$3.77 million
  • Cash and cash equivalents of $2.58 million as of June 30, 2026
  • Current ratio of 7.70 indicates strong liquidity position
Lakewood-Amedex Biotherapeutics Inc. operates in the biotechnology sector, with a focus on addressing critical health challenges through its innovative product offerings. The company has a dedicated team working on research and development, aiming to bring effective solutions to the market. Despite recent financial challenges, the company maintains a robust liquidity position, which may support future growth initiatives. The increasing global demand for antiviral therapies presents significant opportunities for Lakewood-Amedex, making it a noteworthy entity in the biopharmaceutical landscape.
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Kelvin Cooper, PhD

Website

www.lakewoodamedex.com

Headquarters

University Park, FL 34201, US

LABT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

1687.68%

Return on Capital

N/A

Return on Assets

-148.13%

Earnings Yield

-4.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.37M

Volume

502.83K

Avg. Volume

1.67M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$7.27M

EBITDA

-$7.20M

Operating Cash Flow

-$3.49M

Capital Expenditure

$0.00

Free Cash Flow

-$3.49M

Cash & ST Invst.

$4.58M

Total Debt

$101.62K

Lakewood-Amedex Biotherapeutics Performance Analysis

Lakewood-Amedex Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Lakewood-Amedex Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Lakewood-Amedex Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -12.20N/A
20242024-12-31USD -7.00-42.6%
20252025-12-31USD -8.4020.0%
Lakewood-Amedex Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3017.5%
Q42025-12-31-184.7%
Q12026-03-3148.7%
Q22026-06-30-37.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.18M

N/A

Employees

5

N/A

Net Income

-$3.77M

-475.1%

EBITDA

-$3.76M

-491.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.58M

N/A

Total Debt

$101.62K

N/A

Accounts Receivable

$4.53K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$101.62K

N/A

Return on Assets

-1.48%

N/A

Return on Invested Capital

-1.68%

N/A

Free Cash Flow

-$2.10M

N/A

Operating Cash Flow

-$2.10M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WETOWetour Robotics
$5.48-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.92+0.00%
IBITiShares Bitcoin Trust
$44.67+0.02%
INTCIntel
$89.51+0.00%

Questions About LABT

What is the current price of Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics is trading at $2.50 per share.

What is the 52-week range for Lakewood-Amedex Biotherapeutics?

Over the past 52 weeks, Lakewood-Amedex Biotherapeutics has traded between $1.66 and $98.20.

How much debt does Lakewood-Amedex Biotherapeutics have?

As of the most recent reporting period, Lakewood-Amedex Biotherapeutics reported total debt of $101.62K.

How much cash does Lakewood-Amedex Biotherapeutics have on hand?

Lakewood-Amedex Biotherapeutics reported $2.58M in cash and cash equivalents in its most recent financial results.

What is Lakewood-Amedex Biotherapeutics’s dividend yield?

Lakewood-Amedex Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services